Abbott Cert. Bid Says Nixing Pay-For-Delay Will Kill Innovation

By Django Gold (November 16, 2012, 4:42 PM EST) -- An Abbott Laboratories subsidiary on Tuesday asked the U.S. Supreme Court to consider the Federal Trade Commission's antitrust challenge to "pay-for-delay" drug patent settlements, arguing that impeding such deals will threaten innovation in the pharmaceutical industry, while two other companies said intervention was unwarranted....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!